Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

Brefeldin A

For research use only.

Catalog No.S7046

32 publications

Brefeldin A  Chemical Structure

CAS No. 20350-15-6

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Brefeldin A has been cited by 32 publications

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 M1PYVmZ2dmO2aX;uJGF{e2G7 MVeyJO69VQ>? MoK5NUBp NVPjXopTcW6qaXLpeJMhfGinIFytSG9RSSBqMkFCpO69VSlvaX7keYNm\CC2cnHud4lmdnRiRWLLNU8zKHCqb4PwbI9zgWyjdHnvcuKh MoL6NlY{PjNzOUG=
C2C12 M33xR2Z2dmO2aX;uJGF{e2G7 NHPp[4IyyqEQvHevcYw> MXmxxsBp M4LHPIFjd2yrc3jld{BkgXSxa3nu[UBz\WynYYPlJIZzd21iQ{LDNVIhdXmxdIXi[ZM> NYiyTXlDOjZ{OUGyO|k>
MEFs WT M3;Zd2Z2dmO2aX;uJGF{e2G7 NICwfXo2yqEQvF2= NEjwNZEzOCCvaX6= Mn;yZ4F2e2W|IILld4ll\W62IHXufplu\XNic4XjbEBieyCQQVfUMWdHWCxidH:g[Iln\nW|ZTDiZYNsKHSxIITo[UBGWg>? NV;yZnJqOjZzOU[wNlM>
MEFs VAMP7 KO MVrGeY5kfGmxbjDBd5NigQ>? NV7mSGNkPcLizszN MVeyNEBucW5? M3TZNoNifXOnczDy[ZNq\GWwdDDlcpp6dWW|IIP1Z4gh[XNiTlHHWE1ITlBuIITvJIRq\m[3c3WgZoFkcyC2bzD0bIUhTVJ? MX2yOlE6PjB{Mx?=
SMCs M1qwNmZ2dmO2aX;uJGF{e2G7 M17qUFExyqEEtXevcYw> NHX5S|ExNTF{IHi= MYnEUXNQ MVXzbI94eyCjIITy[Y5lKHSxd3Hy[JMh[SCqaXfo[ZIh[2:wY3XueJJifGmxbjDv[kB1cGViRWKvV3IhdmW2d3;yb{BqdiC2aHWgdIVzcW63Y3zlZZIh[XKnYdMg NUXhdm9tOjZzN{KwPFA>
SMCs NHXTXpBHfW6ldHnvckBCe3OjeR?= MX2xNOKhyrWpL33s NXntb5NGOC1zMjDo NVrYemk2TE2VTx?= NVvkb2Vw[2G3c3XzJIEhfHKjboPp[Y51KEOjMjxCpJJmdGWjc3Wg[pJwdSC2aHWgSXIwW1MEoB?= NFm1d2ozPjF5MkC4NC=>
HEMC-1 MlLCSpVv[3Srb36gRZN{[Xl? NXXhcVNxOC5zwrFCuYcwdWx? M2XLfVI1yqCq NHnKd2dk[XW|ZYOgZUBpcWeqZYKgbY5pcWKrdH;yfUBm\m[nY4Sgc44h\XixY4n0c5NqeyC2aHHuJI5w[2:mYYrvcIU> NVXEb4NXOjV7N{K3OVk>
HUVEC NYC3fZd{TnWwY4Tpc44hSXO|YYm= NXfTRlJnOTEEoN88US=> M2XUeVHDqGh? NHKyZ2ZFVVOR MlLxZYJwdGm|aHXzJIh6eG:6aXGtbY5lfWOnZDDy[Yxm[XOnIH;mJGFVWCCocn;tJIFxcWOjbDDhcoQh[mG|b3zheIVz[Wxic4Xy[oFk\XN? MXmyOVk2Pjl6OB?=
HUVEC MWPGeY5kfGmxbjDBd5NigQ>? MmW1NVDDqM7:TR?= MXexxsBp MoDQSG1UVw>? NFzXSpRqdmO{ZXHz[ZPDqHSqZTDueY1j\XJiYX7kJIlvfGWwc3n0fUBw\iCobIXvdoV{[2WwdDDhdoVieyCnc4DlZ4lidGy7IHnuJJBmemmwdXPs[YFzKHOyYXPl NIHjNVkzPTl3Nkm4PC=>
Caco-2 NUXjOGV3TnWwY4Tpc44hSXO|YYm= NIO4WngzNjVizszN MmjiN|AhdWmw MWfheJRmdnWjdHXzJJRp\SCWR1[t{tIyNW2nZHnheIVlKGmwY4LlZZNmKGmwIGPFVnQh\nWwY4Tpc44> NX:0U3J2OjV7NUS5N|E>
NRK M{LFVWZ2dmO2aX;uJGF{e2G7 M3;hdVIxOOLChX7nM41t MV:05qCGcA>? NHnGWIpFVVOR M4O0ZZJme2O3ZYOgcYl1d3SrYzDwdo9oemW|c3nvci=> M{fDPVI2QTR6NUi2
HeLa M{LMXmZ2dmO2aX;uJGF{e2G7 MkXKNlAx6oDHbnevcYw> MlTNN{Bp M3Lid2ROW09? MnuybY5lfWOnczD0bIUh[XK2aX\pZ4lidCCkcnXhb{12eCCxZjD0bIUhT2:uZ3mgZ49ueGyneB?= MXGyOVk1QDV6Nh?=
COS M1TuTGZ2dmO2aX;uJGF{e2G7 MkWzNUDPxGdxbXy= NUH3bpVsOyCq NHzPcHFkd22ybHX0[Yx6KGSrc4DldpNmeyC2aHWgRXAuOSC|aXfuZYzDqA>? NXG3NpY6OjV7MUW5NFA>
DF1  NFnYTpBHfW6ldHnvckBCe3OjeR?= NXHXd|I4OcLizszNxsA> NFzRPZE1QCCq NGPISFhFVVOR NXLqUI9t\Gm|cHXyd4V{yqC2aHWg[Zhw\2Wwb4XzJGNUT2GuTlHjWFIheHKxdHXpci=> MX6yOVgxPzB3NB?=
nHDFs  M2Xz[WZ2dmO2aX;uJGF{e2G7 NGD3dlIyyqEQvF5CpC=> M2T6[FLDqGh? NF\QSXBxemW4ZX70d{B1cGViYYPz[Y1jdHlib3[gZ5l1d3OxbHnjJINw[XRicILveIVqdnNib370c{BId2ypaTDt[Y1jemGwZYO= NXX1PZVwOjV5N{K2NVY>
FRT  NGr4cIlHfW6ldHnvckBCe3OjeR?= M4m0cVUh|rypL33s NILFNIQzyqCq M{C5R4Jtd2OtczD0doFn\mmla3nu[{B1cHKxdXfoJJRp\SCJb3znbUBkd22ybHX4JIJ6KGmwaHnibZRqdmdiRWKteI8uT2:uZ3mgeJJidnOyb4L0 NHnuZ5kzPTd4N{GxOS=>
FRT  MmDnSpVv[3Srb36gRZN{[Xl? NEn4eVU2KM7:Zz;tcC=> Mlf2NuKhcA>? NVfnTFJpeHKndnXueJMhfGinIHnuZ5Jm[XOnIHnuJINt\WG4ZXSg{tEhe3WkdX7peJMhf2inbjDbUoEsZWoEoIfhd{Bz\WS3Y3Xk NIXjcG4zPTd4N{GxOS=>
HepG2  Mn23SpVv[3Srb36gRZN{[Xl? MYGx5qCKyrWPwrC= NYjMPWk5OjRiaB?= NEPB[|VFVVOR M1K4fIRm[3KnYYPld{B1cGVibHX2[Ywhd2ZiUGjSJI1TVkF? NVTHSGdvOjV4MU[1PVc>
SMCs MWrGeY5kfGmxbjDBd5NigQ>? MkPyNe69\y:vTB?= M1jlPVMhcA>? NHWwdJpi[2O3bYXsZZRmeyCFTmDZNkBxem:2ZXnuJIlvKHSqZTDFVkBkd22yYYL0cYVvfCCjbnSgco8hdG:wZ3XyJINwNWyxY3HsbZpm\CC5aYToJJRp\SCJb3znbUBu[XKtZYNCpC=> MUSyOVU5QTR{NR?=
OB-6 M2G1dWFxd3C2b4Ppd{BCe3OjeR?= M4iwUVIvP8LizszN NEX5T2s1QCCq MlnVbY5lfWOnczDhdI9xfG:|aYO= NUDUWY5qOjV3M{K0PFA>
iPSC-CMs  MUHGeY5kfGmxbjDBd5NigQ>? NG\IVVc2ODBibnevcYw> MoXTOFghcA>? MVHpcoNz\WG|ZYOgeIhmKGmwdHXud4l1gSCxZjD0bIUhcGmpaHXyJI1w[mmuaYT5JGxCVVC|IHH0JJRp\SClb4P0JI9nKHSqZTDsc5dmeiCvb3LpcIl1gSC|cHXjbYV{ MmDLNlU1QDh4Nk[=
SP-Nluc NGracFRHfW6ldHnvckBCe3OjeR?= MXG1JI1oN22O MonXOkBp MXnEUXNQyqB? NXSxOlRY[2G3c3XzJIFvKGmwY4LlZZNmKGmwIILldI9zfGW{IHHjeIl3cXS7IHnuJJRp\SCyYYLhd4l1\Q>? M3z4NVI2Ozl{OUm4
PEXEL-Nluc MmLDSpVv[3Srb36gRZN{[Xl? NVrxZYg3PSCvZz;tUC=> M4jsflYhcA>? NXPCdpg3TE2VT9Mg MXXjZZV{\XNiYX6gbY5kemWjc3WgbY4hemWyb4L0[ZIh[WO2aY\peJkhcW5idHjlJJBiemG|aYTl NXTWWXpXOjV|OUK5PVg>
H1299 NEixR2xHfW6ldHnvckBCe3OjeR?= NE\GTHMyOCEQvHevcYw> NUjj[o9IOjRiaB?= NXfpT5FOcW6mdXPld{BifXSxcHjh[5nDqA>? NInWTHIzPTN6OEm3NC=>
MDA-MB-231 M1m3dWNmdGxiVnnhZoltcXS7IFHzd4F6 MnnrNQKBmzVyIN88[{9uVA>? Mk\POFghcA>? M4PJV2VEPTEEoE2gNE4xOTZiwsXnM41N M2OzXVI2OzV4NU[3
MDA-MB-231 NFraXIJCeG:ydH;zbZMhSXO|YYm= MVmwMlEh|rypL33M NVTIOFFKPCCq NEL5W2VqdmS3Y3XzJIFxd3C2b4Ppdy=> NVnTeGtqOjV|NU[1Olc>
MDA-MB-231 NXnoeJNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjS[o4xNjBzL{CuNFUh|rypL33M M1OxRVI1KGh? MXzpcoNz\WG|ZYOgeIhmKG[{YXP0bY9vKG:oIIP1Zk1IOSClZXzsJIRm[nKrcx?= NYjuS3JWOjV|NU[1Olc>
MDA-MB-231 NUfVZlBZSXCxcITvd4l{KEG|c3H5 M3fUd|AvODYkgKOxJO69\y:vTB?= NFXBd|czPCCq NXGzTVNScW6mdXPld{BRSVKSIDjwc4x6KEGGUD3ybYJwe2VicH;sfY1memG|ZT2xLUBkdGWjdnHn[S=> M1:0[VI2OzV4NU[3
MDA-MB-231 M3naeGZ2dmO2aX;uJGF{e2G7 MWWw5qCUPTBizsznM41N Mmq5NlQhcA>? NHPid|ZqdmirYnn0d{B1cGViZn;ycYF1cW:wIH;mJFNFKGGwZDCySEBkd2yxbnnldy=> NYDYNYY3OjV|NU[1Olc>
A172 NVf4NpB6TnWwY4Tpc44hSXO|YYm= NFfP[IsyOMLizsznM41t NYPUeIRbPMLiaB?= NH7HN4dFVVORwrC= MnXrdoV{fWy2czDpckB1cGVicnX0do9oemGmZTD0doFve3CxcoSgc4Yh\my3b4Lld4NmdnRiZ4LhcpVt\XN? NHH3XnMzPTJ|OUWwOy=>
KMS-6 MULGeY5kfGmxbjDBd5NigQ>? NU\VUYRtOcLizszNxsA> NEH2eGgzPCCq MYXlfIhq[mm2czDoZYxnKHSqZTDz[YNz\XSrb36gc4Yh\2GuYX7pck1NUSCjczDkbYQhfGinIHPvcpRzd2x? MlHlNlUzOjlzMk[=
MEC MlfXSpVv[3Srb36gRZN{[Xl? MUKxJO69VQ>? Mn3iNU42KGh? NIfJXlVk[XW|ZYOgZUBlemGvYYTpZ{Bl\WO{ZXHz[UBqdiC2aHWgd5Vz\mGlZTDWSWdHWjJ? NFHuVYwzPTJ{OEixOS=>
HEK293/hERG MonuSpVv[3Srb36gRZN{[Xl? NH3sRmIyOMLizszN NEHkbJAyyqCq MonhdoV{fWy2czDpckBiKHSrbXWt[IVx\W6mZX70JJJm\HWldHnvckBu[XS3cnWgbGVTTyCycn;0[YlvyqB? Mk\1NlUzOTh2Nkm=
RBE4 M2LX[2Fxd3C2b4Ppd{BCe3OjeR?= MlzrNuKh|ryP NV7lc3NDO+LCk{K0xsBp NEXic2RqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHTldIVv\GWwdHz5 MnnUNlUyOjhyMkW=
RBE4 NFrFcmJHfW6ldHnvckBCe3OjeR?= M1zRTVLDqM7:TR?= M2S0[VPjiJN{NNMgbC=> NVnpNItEcW6lcnXhd4V{KHSqZTDYRnAyKHC{b4TlbY4hdGW4ZXzzJIFnfGW{IEOgZY5lKDcEoHigc4YhfHKnYYTt[Y51 M4PEXlI2OTJ6MEK1
RBE4 Ml3iSpVv[3Srb36gRZN{[Xl? M1P2XlLDqM7:TR?= NEXscmg{6oDVMkVCpIg> MVXpcoNz\WG|ZYOgZYN1cX[nIHPhd5Bie2VvMUKgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=> M1P0XFI2OTJ6MEK1
RBE4 NWP5PWNVTnWwY4Tpc44hSXO|YYm= M3exbFLDqM7:TR?= NXvtfId7O+LCk{K0xsBp NID4SGxqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDSU3MhfGmvZT3k[ZBmdmSnboTsfS=> MoHQNlUyOjhyMkW=
RBE4 MXTGeY5kfGmxbjDBd5NigQ>? NWm2TJBTOsLizszN NULDPXJmO+LCk{K0xsBp NV3MV49xcW6mdXPld{BiKGSnbHH5[YQh\GWybHX0bY9vKG:oIITo[UBGWiCFYUKrxsBkd262ZX70JIF1KDcEoHigc4YhcW6ldXLheIlwdiC|aXfubYZq[2GwdHz5 NF;EdnQzPTF{OECyOS=>
RBE4 MmnsSpVv[3Srb36gRZN{[Xl? MXiyxsDPxE1? MXiz5qCUOjUEoHi= NXG0U3hycW6mdXPld{BidiCxdnXycI9i\CCxZjDDZVIsyqCrbjD0bIUhdWm2b3Poc45lemmjIHnuJJRp\SCoaYLzeEA3yqCqIH;mJIlv[3WkYYTpc44hMHEkgJm85qCKOC5yMEGpJIJ2fCCFYUKrxsBt\X[nbIOgbY4hfGirczDvdodidmWubHWg[IVkemWjc3XkJIFnfGW{IEGyxsBpKG:oIHnuZ5Vj[XSrb36= NYn4PXZPOjVzMkiwNlU>
Huh-7  M{m1TmZ2dmO2aX;uJGF{e2G7 NUnaT2k4Oc7:Zz;tUC=> M4XDVFPjiJN{NNMgbC=> MX\pcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M1K1PFI2ODJ4MUe0
HepG2  NHHMeldHfW6ldHnvckBCe3OjeR?= MmLpNe69\y:vTB?= M{m5TlPjiJN{NNMgbC=> NHu5TJpqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIFHQSVEhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NYPRNmRnOjVyMk[xO|Q>
H838-LKB1 NWDu[VgxTnWwY4Tpc44hSXO|YYm= M1PWclMxyqCwZz;tcC=> MWSxNk8yQCCq NXz1eFFYcW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? NX7se2JSOjVyMUGwPFI>
H838-KDLKB1  Mmn5SpVv[3Srb36gRZN{[Xl? NFHOWFc{OMLibnevcYw> NILqd|YyOi9zODDo MkSwbY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=> NIPGOIszPTBzMUC4Ni=>
H838-KDLKB1  NIHzNpdHfW6ldHnvckBCe3OjeR?= M{ewUlMxyqCwZz;tcC=> NGCzTWgyOi9zODDo MlPsbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicHjvd5Bpd3K7bHH0[YQh\UmIMt8xJEhxcG:|cHjvMYVKTjMQsTm= M2PKSVI2ODFzMEiy
3T3-L1 M2rudGZ2dmO2aX;uJGF{e2G7 NFL2Ono2KM7:Zz;tcC=> NGHn[W4{OCCvaX6= MkTXcYlucWO|IITo[UBm\m[nY4TzJI9nKGmwc4XsbY4h[W6mIHPheZNmeyC{b3L1d5QheGixc4Doc5J6dGG2aX;uJI9nKEGtdDCoV4VzKDR5MzmgZY5lKHCqb4PwbI9zgWyjdHnvckBw\iCDU{G2NEApXGi{IE[0NkBidmRiU3XyJFU5QCl? NHTPUWwzPDh2M{iyOy=>
3T3-L1 MmHKSpVv[3Srb36gRZN{[Xl? MVe1JO69\y:vbB?= MX:zNEBucW5? M1jIbJJm[2GyaYT1cIF1\XNiaX7zeYxqdiCjY4Tpc44hf2m2aDDy[ZNx\WO2IITvJJJm\3WuYYTpcochSWu2IHHjeIl3cXS7IHHu[EBCWzF4MDDwbI9{eGixconsZZRqd25? M1TzNVI1QDR|OEK3
3T3-L1 MUHGeY5kfGmxbjDBd5NigQ>? MoCyOUDPxGdxbXy= NVH2fGxPOzBibXnu NVfEO|c1[2G3c3XzJJJmfmW{c3nicIUhemWmaYP0doljfXSrb36gc4YhT0yXVES= NEKyeVkzPDh2M{iyOy=>
3T3-L1 Mn[xSpVv[3Srb36gRZN{[Xl? NFTuXJE2KM7:Zz;tcC=> MmPxNeKhcA>? MUDjZZV{\XNicnXkbZN1emmkdYTpc44hd2ZiR1zVWFQh[nW2IH7veEBqdmO{ZXHz[UBqdiCpbIXjc5NmKHWydHHr[S=> M{f1b|I1QDR|OEK3
3T3-L1 MUTGeY5kfGmxbjDBd5NigQ>? Mo\sOUDPxGdxbXy= Ml\MNeKhcA>? MVXjZZV{\XNicHjvd5Bpd3K7bHH0bY9vKG:oIITo[UBHd3iRMTD0doFve2O{aYD0bY9vKG[jY4Tvdi=> MUSyOFg1Ozh{Nx?=
HeLa  Mnu4SpVv[3Srb36gRZN{[Xl? NEDrd4I2KM7:Zz;tcC=> NVi0OJhiOyCq MoHTZ4F2e2W|IH71Z4xm[XJiZYjjcJV{cW:wIH;mJJRp\SCIb4jPNUB1emGwc3PybZB1cW:wIH\hZ5RweiCjbnSg[IVkemWjc3XzJJRz[W6|Y4LpdJRqd25ib3[gSo95VzFvcnXneYxifGWmIHflcoV{ M1Lh[|I1QDR|OEK3
HEK293 NV;zdYNNTnWwY4Tpc44hSXO|YYm= NU[wWYZsPcLizsznM41t M{PWd|EzyqCq MYLhZo9tcXOqZYOgR21CNWmwZIXj[YQhS1KHTFSyJJNm[3KndHnvci=> NUWyWmp7OjR4OEe0N|E>
COS-1 NVzYWWZCTnWwY4Tpc44hSXO|YYm= NHS3W2Q2KML3Zz;tcC=> MkTyNlQhcMLi MkHYdoV{fHKrY4TzJIxw[2GuaYrheIlwdiCxZjDORkBqdiC2aHWgdIVzcW63Y3zlZZIhemWpaX;uxsA> M4\JWFI1PjdzN{Wx
PRP MUHGeY5kfGmxbjDBd5NigQ>? NG\r[IUyOCEQvF2= MkLQZYJzd2ejdHXzJHNFTi1zzsGtcYVlcWG2ZXSgR3hEWjdiZYj0[ZJv[WyrenH0bY9vyqB? NEfGSI4zPDZ4OEe1NC=>
RAW264.7 NIfwbm9CeG:ydH;zbZMhSXO|YYm= NEPuZYY1KM7:TR?= NHnvOGM1QCCq MkfZZZR1\W63YYTld{B1cGViaX7obYJqfGmxbjDv[kBwgC2ORFytbY5lfWOnZDDhdI9xfG:|aYOgZY5lKHSqZTDmZYNqdGm2YYTpc44hd2ZiY3jvcIV{fGW{b3yg[YZndHW6IHL5JGFkNWiHLUG4RU1PUDJ? MonyNlQ3OzlyM{K=
MDMs NX3lc2dPSXCxcITvd4l{KEG|c3H5 MYqxNQKBkc7:Zz;tcC=> M2fwSVEzNzF3IHi= MVHpcoR2[2W|IHHwc5B1d3Orcx?= MVmyOFU2PjZ7NR?=
PMHs  NH\wRoVHfW6ldHnvckBCe3OjeR?= M3P1d|Ex6oDVMkFihKnPxGdxbXy= MkfONlTjiImq NVzhPJZYTE2VTx?= MlPQbY5lfWOnZDDFVkB{fHKnc4O= MkLoNlQ1ODd{NEK=
PMHs  MV;BdI9xfG:|aYOgRZN{[Xl? MoO3NVDjiJN{MPMAje69\y:vbB?= NH3VNGkzPOLCiXi= M4OyWmROW09? NV3BSJZ{cW6lcnXhd4V{KGOnbHyg[IVifGh? NYLDSZQ2OjR2MEeyOFI>
HEK293/tau NHrtR3pHfW6ldHnvckBCe3OjeR?= MY[1JO69VQ>? NIe1WFcyNzJxNDDo Mlm5bY5lfWOnczDHc4xocSCocnHncYVvfGG2aX;uxsA> MYCyOFM3QDB6OR?=
HEK293/tau NGnEV5pHfW6ldHnvckBCe3OjeR?= NFzBXGg2KM7:TR?= NFfjNoQ{KGh? MWfpcoR2[2W|IITheUBpgXCncoDoc5NxcG:{eXzheIlwdg>? M2fXVFI1OzZ6MEi5
ADF MmjiSpVv[3Srb36gRZN{[Xl? M2myO|ExKM7:TR?= MmrvNVYhcA>? MmTmbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> MY[yOFIzQDJ|Mh?=
U373  M1[4WGZ2dmO2aX;uJGF{e2G7 MWKxNEDPxE1? M2T0XlE3KGh? MYjpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> NVfHO2ZIOjR{MkiyN|I>
RKO-HIPK2i NYPadnN1TnWwY4Tpc44hSXO|YYm= MoPNNVAh|ryP NIC2fHUyPiCq NYKwUlJlcW6qaXLpeJMhfGinIGruR4wzNWmwZIXj[YQhfHKjboPsc4NifGmxbjDv[kBEWlR? MljtNlQzOjh{M{K=
ADF  M1X1WWZ2dmO2aX;uJGF{e2G7 NWPnSpg4OTBizszNxsA> NHLwT5M3KGh? MYXpcZBicXK|IITo[UBFSyCjY4TpeoF1cW:w NGXRTXEzPDJ{OEKzNi=>
Huh7 M{W4[2Z2dmO2aX;uJGF{e2G7 MnPyOUDPxGdxbXy= M2LaPFQhcA>? Mli5ZYJwdGm|aHXzJJRp\SC|ZXPy[ZRqd25ib3[gJIlvfHKjY3XscJVt[XJiQYDvRi=> MWeyOFExODF2MB?=
Huh7 NIH3TZRHfW6ldHnvckBCe3OjeR?= M{mwOFUh|rypL33s NIHOWZIyKGh? MYLjZZV{\XNiYTDzbYdvcW[rY3HueEBqdmO{ZXHz[UBqdiCDcH;CMYNz\XOlZX70dy=> NXSwelVmOjRzMECxOFA>
Huh7 MWDGeY5kfGmxbjDBd5NigQ>? MnLBOgKBmzFywrDu[{9udA>? NWDXdnJlOTJiaB?= M4DGXIlv[3KnYYPld{BCeG:ELXPy[ZNk\W62czD3bZRpd3W2IHnubIljcXSrbnegd4VkemW2aX;u MUiyOFExODF2MB?=
BAECs MlHBSpVv[3Srb36gRZN{[Xl? MVW1JO69\y:vbB?= MVywMVQhcA>? Mon1bY5lfWOnczD0bIUhemGyaXSg[IVxcG:|cHjvdplt[XSrb36gc4Yh\U6RUzDheEBU\XJzMUe5 MlHyNlQxQDV{MkW=
Macrophages Ml60SpVv[3Srb36gRZN{[Xl? NEj5fZU4OSEEtV2= NGq1UWI3KGh? M2\BZolvcGmkaYTzJIx2dmG|aX6gbY51\XKwYXzpfoF1cW:wwrC= MWmyOFA{QTd2MB?=
Colo 205 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjBSmExNTVizsznM41N Mn3jOFghcA>? NIrrbHBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDzeZNx\W6|aX;uJIN2dHS3cnXzJJdqfGhiYX6g[ZN1cW2jdHXkJGlEPTBib3[gglE2KG6pL33M MX:yN|k4Ozl7Nh?=
Colo 205 MYXGeY5kfGmxbjDBd5NigQ>? NUXaZXFXOC5yMUKtNE4xOjVizsznM41N MY[xOEBl M{i4fpJm\HWlZYOgeIhmKGOub37v[4VvcWOrdImgc4YhS2:ubzCyNFUhS1OFcx?= M3zQN|I{QTd|OUm2
Colo 205 NFPaPIpCeG:ydH;zbZMhSXO|YYm= NEO3SYYxNjFizsznM41N NFrYT3MxNTJ2IHi= MV7pcoR2[2W|IHHwc5B1d3OrczDv[kBEd2yxIEKwOUBk\WyuczDpckB{fXOyZX7zbY9vKGO3bIT1doV{ NH2wXXYzOzl5M{m5Oi=>
Colo 205 NEPhclBHfW6ldHnvckBCe3OjeR?= NVvsVWtQOC5yMUWg{txoN22O MUOyOEBp M1TF[Ylv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gSXIhe3S{ZYPzMZJmdGG2ZXSg[4Vv\XN? M4PjcVI{QTd|OUm2
Colo 205 MlnxSpVv[3Srb36gRZN{[Xl? MXKwMlAyPSEQvHevcWw> Mn\xNlQhcA>? Mln4bY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIF3NVJM> NXjIUHZJOjN7N{O5PVY>
IBRS2 M3HHeGZ2dmO2aX;uJGF{e2G7 NXTDSIJnPSEQvHevcYw> MX6wMlUhcA>? NVTYfWg2TE2VTx?= MYDkbZNzfXC2czD0bIUhTVKJSVOgZY5lKEexbHfpxsA> M2[0SVI{QTZ|NUO0
IBRS2 NV\WSlY{TnWwY4Tpc44hSXO|YYm= MXW1JO69\y:vbB?= MXqwMlUhcA>? NYL3Sok5TE2VTx?= NWTDd29q\W6qYX7j[ZMhTk2GVjDpcoZm[3Srb36= NVvOdW8xOjN7NkO1N|Q>
HeLa MorWSpVv[3Srb36gRZN{[Xl? MYGyJO69VQ>? M{jpVFIhcMLi NFPMeWtifHSnboXheIV{KHSqZTDUUmYucW6mdXPl[EB{\WO{ZYTpc44hd2ZiSVytNVU> M1PZOFI{QTVyOEmy
HFS  M1;k[GZ2dmO2aX;uJGF{e2G7 NX;VNJpnOC1zIN88[{9udA>? MkWyNlQhcA>? MWDHUHRRKGW6cILld5Nqd25icnXhZ4hmeyCjIIDsZZRm[XViYYSgZ49v[2WwdILheIlwdnNiYYOgcI94KGG|IECuNFEhyrWpL33s Mnj2NlM5QTR4M{O=
HFS  NEnLNGRHfW6ldHnvckBCe3OjeR?= NVrm[mY1OC5yMTFCuYcwdWx? MXuyOEBp MmjubY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIdtgWOxc4DobY5od2yrcHnkJJN6dnSqYYPlJIdmdmW|IHH0JFYhcA>? MkL4NlM5QTR4M{O=
OVCAR-3 NH;YNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\4NlHjiJNzNdMg{txOyqB? MXqyOOKhcA>? Ml6xbY5lfWOnczDhJIxwe3Nib3[gZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgcLi MX2yN|gzPjl4NB?=
OVCAR-3 MXTGeY5kfGmxbjDBd5NigQ>? MliyNgKBmzF3wrFOwG3DqA>? NVTuR4JOOjUEoHi= NEHueHVqdmS3Y3XzJI52[2ynYYKg[IFu[Wen M1THWlI{QDJ4OU[0
OVCAR-3 M4fzT2Fxd3C2b4Ppd{BCe3OjeR?= NU\RNnNCOS1zMNMg{txO MYG0JIg> MoG4bY5lfWOnczD0bIUh[WO2aY\heIlwdiCxZjDhdI9xfG:|aYOtdoVt[XSnZDDwdo91\Wmwcx?= NGrtOY4zOzh{Nkm2OC=>
OVCAR-3 MYLBdI9xfG:|aYOgRZN{[Xl? MV2xNOKh|ryP NH35fVAzPMLiaB?= Mof6bY5lfWOnczDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4V{ M3yx[FI{QDJ4OU[0
OVCAR-3 MW\GeY5kfGmxbjDBd5NigQ>? M4Tu[FHjiJNzMNMg{txO NV3vOWE3OjUEoHi= MoLWbY5lfWOnczDkbZNzfXC2aX;uJI9nKHSqZTDtbZRw[2ixbnTybYFtKHS{YX7zcYVu[nKjbnWgdI91\W62aXHs MmTxNlM5OjZ7NkS=
OVCAR-3 MUPGeY5kfGmxbjDBd5NigQ>? M4\MSFHjiJNzMNMg{txO M4PoWVI1yqCq MXzpcoR2[2W|IH\vdo1ifGmxbjDv[kBz\WGldHn2[UBwgHmpZX6gd5Bm[2mncx?= MoXTNlM5OjZ7NkS=
OVCAR-3 NV74TpVDTnWwY4Tpc44hSXO|YYm= MoTyNgKBmzFywrFOwG0> NF3GOIQzPMLiaB?= MYPpcohq[mm2czDj[YxtKGGmaHXzbY9vKGGwZDDtbYdz[XSrb36= M2nvPFI{QDJ4OU[0
MKN45 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G1e2lEPTB:MD6wNFEh|rypL33s MnG0NlM4QTN|NEK=
LOVO M3L2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPrXIxyUUN3ME2wMlEzKM7:Zz;tcC=> MX[yN|c6OzN2Mh?=
A549 NHi0XWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jRc2lEPTB;MD6wOEDPxGdxbXy= MV6yN|c6OzN2Mh?=
MDA-MB-435 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DhfmlEPTB:MD6wNFEh|rypL33s NEnFRmkzOzd7M{O0Ni=>
HepG2 NVzIcpl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnvNWg4UUN3MEywMlAxOSEQvHevcYw> NIf6SGQzOzd7M{O0Ni=>
HL-60 NWryS|J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjQcnhKSzVyPECuNFAyKM7:Zz;tcC=> MojHNlM4QTN|NEK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / GRP78 ; 

PubMed: 22859938     


(B) present the dose- and time- dependent effect of ER stress inducer brefeldin A on p53 expression. MCF-7 Cells were exposed to brefeldin A in 10% FBS–supplemented DMEM as time and dose indicated. The cell lysates were analyzed by western blotting with antibodies for p53, GRP78, and α-tubulin. The p53 protein expression level was quantified densitometrically. GRP78 served as an ER stress marker. 

22859938
Immunofluorescence
MTP / GBF1 ; 

PubMed: 26267806     


3T3-L1 cells, plated as above, were treated with brefeldin A (5 μg/ml, 3 hr), fixed and stained for MTP and GBF1. Brefeldin A treatment leads to redistribution of MTP from the juxtanuclear region, similar to what occurs with GBF1. Bars = 10 μm.

ErbB3 / Calnexin ; 

PubMed: 21576364     


293T cells transfected with ErbB3 were treated without (top) or with (bottom) BfA, and confocal immunofluorescence microscopy was used to examine the colocalization of ErbB3 with endogenous calnexin.

FMNL1 / GM130 ; 

PubMed: 21868368     


FMNL1 colocalizes with the cis-Golgi marker GM130 and is dispersed by treatment with brefeldin A (+BFA).

26267806 21576364 21868368
Growth inhibition assay
Cell viability; 

PubMed: 28462831     


Effects of brefeldin A on human prostate cancer cells. LNCaP and PC-3 cells were seeded in cell culture dishes and incubated for 24 h. The cells were then treated with different concentrations of brefeldin A for 72 h. The number of viable cells was determined by the trypan blue exclusion assay. Apoptosis was determined by propidium iodide staining and morphological assessment.

28462831

Protocol

Cell Research:

[5]

- Collapse
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A
Smiles CC1CCCC=CC2CC(CC2C(C=CC(=O)O1)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID